OncoGenex reports target number of events reached in Phase 3 SYNERGY trial OncoGenex Pharmaceuticals announced that the pre-specified number of events required for final analysis of the Phase 3 SYNERGY trial has been reached. The primary efficacy endpoint of SYNERGY will analyze overall survival benefit for custirsen in combination with standard first-line docetaxel chemotherapy and prednisone in men with metastatic castrate-resistant prostate cancer. Overall survival results will remain blinded until all study data have been thoroughly reviewed and prepared for final analysis. Custirsen received Fast Track designation from the FDA for the treatment of progressive metastatic prostate cancer in combination with docetaxel/prednisone. The FDA also agreed on the design of the SYNERGY trial via the Special Protocol Assessment process.
News For OGXI From The Last 14 Days
Check below for free stories on OGXI the last two weeks.